The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs.
悖論的前提:探討促使 GIPR agonist 與 antagonist 藥物開發計畫的相關證據
J Clin Med 2025-06-13
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.
Liraglutide、Semaglutide 或 Tirzepatide 停藥後體重回升:隨機研究的敘述性回顧
J Clin Med 2025-06-13
Complexity of Metabolic dysfunction-associated steatotic liver disease (MASLD): State of art review.
代謝功能異常相關脂肪性肝病(MASLD)的複雜性:現況綜述
J Chin Med Assoc 2025-06-13
Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence.
小檗鹼作為多靶點治療肥胖的藥物:從藥理機制到臨床證據
Eur J Med Res 2025-06-12
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia.
semaglutide 對於服用 clozapine 並合併肥胖之思覺失調症患者的療效與安全性(COaST):澳洲第二期、多中心、參與者與研究人員雙盲、隨機對照試驗
Lancet Psychiatry 2025-06-12
GLP-1 receptor agonists and hospitalization due to infections in patients with type 2 diabetes: A nationwide cohort study.
GLP-1 受體促效劑與第二型糖尿病患者因感染住院之關聯:全國性世代研究
Diabetes Res Clin Pract 2025-06-12